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Abstract
Objective: Gonadotropins (luteinizing hormone (LH) and follicle-stimulating hormone 
(FSH)) are released from the pituitary gland and stimulate Leydig cells to produce 
testosterone and initiates spermatogenesis. Little is known about how and when 
the deterioration of semen quality occurs in patients with adult-onset gonadotropin 
insufficiency.
Design and methods: A retrospective study comprising 20 testosterone-deficient 
men (median age, 29 years) with acquired pituitary disease who delivered semen 
for cryopreservation before initiation of testosterone therapy. Semen variables and 
hormone concentrations were compared to those of young healthy men (n = 340).
Results: Thirteen of 20 patients (65%) and 82% of controls had total sperm counts above 
39 million and progressive motile spermatozoa above 32% (P = 0.05). For the individual 
semen variables, there were no significant differences in semen volume (median 
(intraquartile range) 3.0 (1.3–6.8) vs 3.2 (2.3–4.3) mL, P = 0.47), sperm concentration 41 
(11–71) vs 43 (22–73) mill/mL (P = 0.56) or total sperm counts (P = 0.66). One patient had 
azoospermia. Patients vs controls had lower serum testosterone 5.4 (2.2–7.6) vs 19.7 
(15.5–24.5) nmol/L (P = 0.001), calculated free testosterone (cfT) 145 (56–183) vs 464 
(359–574) pmol/L (P < 0.001), LH 1.5 (1.1–2.1) vs 3.1 (2.3–4.0) U/L (P = 0.002) and inhibin 
b (P < 0.001). Levels of FSH were similar (P = 0.63). Testosterone/LH ratio and cfT/LH ratio 
were reduced in patients (both P < 0.001).
Conclusions: Despite Leydig cell insufficiency in patients with acquired pituitary 
insufficiency, the majority presented with normal semen quality based on the 
determination of the number of progressively motile spermatozoa. In addition, the data 
suggest reduced LH bioactivity in patients with pituitary insufficiency.
Introduction
The gonadotropins, luteinizing hormone (LH) and 
follicle-stimulating hormone (FSH) are released from the 
gonadotropic cells in the anterior pituitary gland. In men, 
the main target cells for LH are Leydig cells with subsequent 
testosterone secretion. FSH primarily stimulates Sertoli 
cells adjacent to germ cells within the seminiferous 
tubules. Intratesticular testosterone stimulated by 
LH, and stimulation of Sertoli cells by FSH seems both 
important for induction of spermatogenesis in humans, 
although some controversy exists (1, 2). Through negative 
feedback, testosterone is the predominant regulator of 
LH, whereas inhibin b is the predominant regulator of 
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FSH (2). Congenital hypogonadotropic hypogonadism 
(CHH) is associated with an infantile phenotype with lack 
of testicular growth and absent testosterone and sperm 
production. In contrast to CHH, normal testicular volume 
can be observed in patients with acquired adult-onset 
hypogonadotropic hypogonadism (3, 4).
The vast majority of patients with adult-onset 
pituitary insufficiency, independent of reason, have 
partial insufficiency with detectable but inappropriately 
low levels of pituitary hormones including gonadotropins 
(5), and the condition will usually result in testosterone 
deficiency at some point (6, 7). However, little is known 
about how and when deterioration of semen quality 
occurs in these patients. Previous studies have primarily 
examined semen quality in prolactinoma patients with 
reversible hypogonadism, and the effect of dopamine 
agonist treatment (8, 9, 10, 11, 12). There are in vitro, 
as well as clinical data, suggesting that prolactin per se 
affects male reproductive tissue in addition to the well-
known suppressive effect on release of gonadotropins 
(13, 14, 15). Therefore, results obtained in patients with 
hyperprolactinemia may not be extrapolated to patients 
with hypogonadotropic hypogonadism due to other 
diseases.
In the present study, we examined semen quality in 
a group of adult men with documented pituitary disease, 
at the time when secondary testosterone deficiency 
requiring testosterone treatment became apparent. The 
aim was to evaluate, if the two components of the gonadal 
axis, spermatogenesis and steroidogenesis, was influenced 
differently by pituitary insufficiency.
Subjects and methods
Participants
It was a single-center retrospective study comprising 
patients from Department of Endocrinology, 
Rigshospitalet University of Copenhagen. Patients with 
pituitary diseases were offered cryopreservation of semen 
for future fertility treatment before testosterone therapy 
was initiated, or in selected younger cases before pituitary 
surgery or radiation therapy. All patients who started 
testosterone therapy between 2002 and 2016 due to 
pituitary diseases were evaluated (n = 409). Forty-seven 
patients (11.5%) desired cryopreservation of semen. A 
diagnosis of hypogonadotropic hypogonadism was based 
on at least two measurements of low testosterone (non-
fasting) with inappropriately low levels of gonadotropins 
and symptoms of testosterone deficiency. This approach is 
in agreement with current guidelines and reflects that there 
is no consensus on strict criteria to make a diagnosis of 
hypogonadotropic hypogonadism (16). Exclusion criteria 
were previous or ongoing treatment with testosterone or 
gonadotropins, onset of testosterone deficiency before 
puberty and testicular disease including cryptorchidism. 
Twenty patients were included in the study and 27 were 
excluded due to: Treatment with gonadotropins (n = 5), 
treatment with testosterone (n = 11), normal plasma 
testosterone on the day of cryopreservation (n = 3), 
childhood-onset hypogonatropic hypogonadism (n = 3), 
bilateral cryptorchidism (n = 2), unable to ejaculate (n = 2) 
and lack of clinical data (n = 1).
Four of the included patients had fathered children 
(2–8 years from conception to cryopreservation of semen).
Data on patient diagnoses are given in Table 1.
The control subjects were part of an ongoing cross-
sectional study of young Danish men who were included 
in collaboration with the Danish military health board 
(17). In Denmark all young men, except those with chronic 
severe diseases, are required to attend a compulsory medical 
examination before they may be considered for military 
service. The overall study population was recruited from 
1996 to 2010 and consisted of 4867 individuals (average 
participation rate 24%) (17). The present study consisted 
of all participants from the year 2005 without a history 
of pituitary or testicular disease including cryptorchidism 
(n = 340).
Levels of reproductive hormones in patients were also 
compared to age-specific reference ranges.
Physical examination
On the day the first semen sample was delivered to the 
semen laboratory, patients and controls underwent a 
physical examination at the Department of Growth and 
Reproduction, including evaluation of gynecomastia 
and assessment of testicular size by a wooden 
orchidometer (Pharmacia and Upjohn, Denmark) and 
by ultrasonographic evaluation. Furthermore, blood 
samples were collected for measurement of reproductive 
hormones.
Semen samples
All semen samples were analyzed at Department of 
Growth and Reproduction at Rigshospitalet. Patients and 
controls had been instructed to abstain from ejaculation 
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for at least 48 h before attendance at the clinic. The semen 
samples were obtained by masturbation into a clean 
tube at a room adjacent to the laboratory. Samples were 
maintained at 37°C during liquefaction analysis. Semen 
analyses were performed based on the WHO guidelines, 
1992, with modifications as previously described (17). 
Semen volume was estimated through weighing of the 
collecting tubes. For the assessment of sperm motility 
phase contrast microscopy (×400 magnification) was done 
on fresh semen samples. Samples were classified as either 
progressive motile (WHO motility classes A + B), non-
progressive motile (WHO C) or immotile (WHO D). Sperm 
concentration was assessed using a haemocytometer 
(Bürker-Türk) on semen samples diluted in a solution 
of NaHCO3, formaldehyde and distilled water. Total 
sperm count was calculated as semen volume × sperm 
concentration, and total number of progressively 
motile spermatozoa as total sperm count × percentage 
of progressively motile spermatozoa. Normal values for 
semen quality was based on the WHO 2010 guidelines 
(sperm counts above 39 million and progressive motile 
spermatozoa above 32%) (18).
In controls, semen characteristics were based on 
a single semen sample, whereas in the patients, it was 
based on the average of available samples (median 2 
(range 1–5)).
Blood samples
Blood samples were drawn from an antecubital vein in 
the non-fasting state. Measurements of all reproductive 
hormone levels in patients and controls as well as the age-
specific reference ranges were done at the same laboratory 
at Department of Growth and Reproduction.
Serum levels of FSH, LH, sex hormone-binding 
globulin (SHBG), testosterone and estradiol were 
measured by time-resolved immunofluorometric assays 
(Delfia, PerkinElmer). Intra-assay and interassay CVs for 
FSH and LH were 3 and 5%. Intra-assay and interassay 
CVs for both SHBG and testosterone were <8 and <5%. 
For estradiol intra-assay and interassay CVs were <4 and 
8%. Serum inhibin b was measured by a specific two-sided 
enzyme immunometric assay (Serotec, UK), intra-assay 
and interassay CVs 15 and 18%. Free testosterone (cfT) 
was calculated assuming a fixed albumin value of 43.0 g/L 
using the calculation suggested by Vermeulen et al. (19).
Statistics
Descriptive statistics were used to summarize the subject 
characteristics. Results are presented as median and 
interquartile range. Continuous variables were compared 
by T-test, whereas categorical data were compared by 
χ²-test. Associations between variables were performed 
by regression analyses, examined for interaction between 
explanatory variables. To approximate normal distribution 
of the residuals reproductive hormone concentrations and 
percentage of motile spermatozoa were natural logarithm 
(ln) transformed, and other semen variables were cubic 
root transformed.
The relationship in patients between total-
testosterone and cfT vs the corresponding LH and 
between inhibin b vs the corresponding FSH were 
compared to controls from the general population 
using two-dimensional bivariate reference charts (20). 
The bivariate reference curves (97.5 percentile) separate 
individuals with an abnormal LH-testosterone (or LH-cfT 
or FSH-inhibin b) combination from individuals with a 
normal combination.
The statistical analyses were performed by SPSS, 
version 22. Two-sided P values <0.05 were considered 
significant.
Table 1 Patients characteristics.
Numbers
Primary diagnosis
  Acromegaly 8
  Prolactinoma 3
  Mixed GH and prolactin secreting 
adenoma
2
  Empty sella 2
  Non-secreting adenoma 2
  Craniopharyngioma 1
  Medulla blastoma 1
  Hypophysitis 1
Hormone substitution
  Thyroxine 5
  Hydrocortisone 5
  Growth hormone 1
  Desmopressin 1
Other treatments
  Somatostatin analogs 2
  Dopamine agonists 5
  Radiation therapy before cryopreservation 
of semen
2
  Pituitary surgery before cryopreservation 
of semen
7
Time since initial diagnosis of pituitary 
disease, months
5 (range 1–108) 
Diagnoses and substitution therapy in the 20 patients with secondary 
testosterone deficiency.
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Ethics
The study was approved by The Danish Data Protection 
Agency (no:2012-58-0004) and conducted in accordance 
with the Helsinki Declaration. It was a retrospective study 
not requiring informed consent.
Results
Characteristics of the 20 patients are provided in Tables 1 
and 2. The 20 included patients were significantly younger 
than the patients who did not desire cryopreservation 
of semen (n = 362), (29 (25–37) vs 53 (38–65) years, 
P < 0.001). Seven of the included patients had pituitary 
surgery before cryopreservation of semen. Patients with 
a history of acromegaly (n = 8), prolactinomas (n = 3) 
and mixed growth hormone and prolactin secreting 
adenomas (n = 2) comprised the largest groups of patients 
(Table  1). Five were treated with dopamine agonist and 
two with somatostatin analogs (Table  1). Five patients 
had slightly elevated s-prolactin (less than 5-times upper 
normal range). Among the ten patients diagnosed with 
acromegaly eight had elevated serum insulin-like growth 
factor 1 (IGF-I) concentrations (z-score between 4 and 
12). Details on other hormone replacement therapies are 
given in Table 1.
The majority of the included patients started 
testosterone therapy soon after cryopreservation of semen. 
In three patients, testosterone treatment was postponed 
to preserve fertility.
Compared to healthy controls, patients were older and 
presented more frequently with gynecomastia (Table 2). 
Serum estradiol was lower in the patients, whereas 
Table 2 Hormone levels and semen quality.
Patients (n = 20) Controls (n = 340) P value Z scores (patients)
Age 29 (25–37) 19 ± 1 <0.001
BMI (patients, n = 9) 26 (21–30) 22 (20–24) 0.14
Abstinence (days) 4 (3–7) 2 (2–3) 0.11
Average testicular volume (orc) (mL) 20 (17–25) 20 (19–25) 0.61
Average testicular volume (US) (mL) 14 (10–18) 14 (11–17) 0.62
Gynecomastia (patients, n = 17), numbers 4/17 5/340 <0.001
Biochemical markers
  Total testosterone (nmol/L) 5.4 (2.2–7.6) 19.7 (15.5–24.5) <0.001 −2.5 (−3.4 to −1.8)
  SHBG (nmol/L) 17 (10–34) 26 (20–34) 0.03 −1.9 (−2.2 to 0)
  Calculated free testosterone (cfT) 
(pmol/L)
145 (56–183) 464 (359–574) <0.001 −2.0 (−2.9 to −1.6)
  LH (U/L) 1.5 (1.1–2.1)  3.1 (2.3–4.0) 0.002 −1.8 (−2.0 to −1.2)
  FSH (U/L) 2.4 (1.4–4.5) 2.2 (1.5–3.3) 0.63 −1.4 (−2.0 to 0.2)
  Estradiol (pmol/L) 40 (20–70) 60 (50–80) 0.001 −1.9 (−2.2 to 0)
  Inhibin B (ng/L) 142 (129–184) 227 (176–285) <0.001 −0.2 (−0.5 to 0.1)
  Estradiol/total testosterone ratio 10.1 (5.0–15.5) 3.3 (2.7–4.1) 0.013
  Total testosterone/LH ratio 3.2 (1.5–4.8) 6.5 (4.6–8.7) <0.001  
  Calculated free testosterone/LH ratio 77 (37–118) 152 (111–206) <0.001  
  Inhibin b/FSH ratio 63 (35–116) 105 (57–171) 0.01  
  IGF-I (µg/L) 628 (253–1161) 279 (233–328) 0.03 4.5 (0.2–10)
  Prolactin (U/L) 250 (128–478)
Semen characteristics
  Semen volume (mL) 3.0 (1.3–6.8) 3.2 (2.3–4.3) 0.47
  Sperm concentration (mill./mL) 41 (11–71) 43 (22–73) 0.56
  Total sperm counts (mill.) 153 (15–288) 136 (65–235) 0.66
  Progressive motile (%) 49 (13–63) 57 (47–67) 0.04
  Progressive motile (mill.) 77 (17–177) 82 (34–140) 0.51
  Non-progressive motile (%) 7 (5–11) 5 (4–7) 0.13
  Non-progressive motile (mill.) 11 (3–22) 6 (3–12) 0.44
  Immotile (%) 41 (32–67) 37 (27–46) 0.14
  Immotile (mil) 56 (19–109) 45 (21–79) 0.8
  Normal semen quality, WHO criteria (%*) 65 82 0.05
Comparisons between patients (n = 20) and controls (n = 340). Descriptive values are shown as medians and interquartile ranges. Hormone levels in 
patients are also compared to an age matched reference population and the results are expressed in standard deviation (s.d.) scores (z-scores).
*Normal semen quality was defined as total sperm counts above 39 million and progressive motile spermatozoa above 32%.
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estradiol/testosterone ratio was significantly higher in the 
patients compared to controls (Table 2). Testicular size was 
similar in patients and controls.
Leydig cell function
Time interval from 1st documentation of serum testosterone 
<10 nmol/L to cryopreservation was in median 105 (IQR) 
30–210 days. Median time interval from initial diagnosis of 
pituitary disease to cryopreservation was 5 months (range 
1–108). On the day semen was cryopreserved, patients 
had lower serum levels of total testosterone (P = 0.001), 
SHBG (P = 0.03), cfT (P < 0.001), LH (P = 0.002) and estradiol 
(P = 0.001) compared to controls (Fig.  1 and Table  2). 
Hormone levels in patients, compared to age-specific 
reference ranges presented as SD scores (z-scores) are also 
given in Table 2. The median z-score for testosterone and 
cfT were minus 2.5 and minus 1.95, respectively. Fifteen 
patients had serum total testosterone below the lower limit 
for age- and assay-specific reference range.
Total testosterone/LH ratio as well as cfT/LH 
ratio was significantly lower in patients compared to 
controls (Table  2). Adjusted for age and concentrations 
of LH serum testosterone and cfT were reduced by 12.4 
(7.4–17.4) nmol/L and 283 (168–399) pmol/L, respectively 
in patients compared to controls (both P < 0.001). There 
were no significant interactions between patients/
controls and LH in the two regression analyses. Serum 
LH was significantly associated to both total testosterone 
and cfT (both P < 0.001), whereas age did not significantly 
influence testosterone or cfT (both P = 0.82). The 
relationship between serum LH vs total testosterone and 
cfT in patients are presented in Fig. 2A and B using two-
dimensional bivariate plots. The patients are compared to 
a reference chart based on simultaneous measurements of 
LH and testosterone (2A) and LH and cfT (2B) (n = 706, 
age 20–50 years) (21). The curved lines in the two figures 
represent the 97.5 percentile reference curves. If the 
point is inside the curve, i.e. is in the upper left corner 
of the plot, the patient has a normal LH testosterone/
cfT combination. The patient is abnormal if the point is 
outside, i.e. to the right or below the curve. As seen in 
the two figures, the majority of patients had an abnormal 
LH testosterone combination and LH-cfT combination. 
When establishing the reference curves testosterone was 
measured by a radioimmunoassay (RIA) (21). Compared 
to the RIA, testosterone is on average measured 17% 
higher by the immunofluorometric assay used in the 
patients (data not shown). For LH and SHBG the same 
assays were used.
Levels of insulin-like growth factor 1 was significantly 
higher in the patients (P = 0.03).
Spermatogenesis
Data on semen quality are presented in Table 2. One of 
20 patients had azoospermia compared to four of the 
340 controls. For the patient with azoospermia data on 
semen volume was not available, and in another patient 
with very low semen volume (0.2 mL), data on sperm 
concentration were not determined.
Levels of inhibin b were reduced in patients (P < 0.001) 
compared to controls, whereas FSH (P = 0.62) did not 
differ. The inhibin b/FSH ratio was also reduced in patients 
(Table 2). The FSH-inhibin b profile was also compared to 
a reference chart in a bivariate plot based on inhibin b 
and FSH measurement (Fig. 3). Despite reduced inhibin b/
FSH ratio, all men had a normal FSH-inhibin combination 
when compared to men from the general population (full 
drawn line). Sixteen of 20 patients also had a normal 
combination when compared to proven fertile men, who 
had fathered children without use of assisted reproductive 
technologies (dotted line). The reference chart was based 
Figure 1
Levels of LH (A), testosterone (B) and calculated free testosterone (cfT) (C) in controls and patients. All individual measurements are presented in the 
figure. Horizontal lines represent the median.
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on measurements in men aged 20–45  years, n = 307 
(general population) and n = 303 (proven fertile men). The 
reference curves were established using the same assays 
for FSH and inhibin b as used in the patients (22).
There was a significantly lower percentage of 
progressively motile spermatozoa in patients compared 
to controls 49 (13–63) vs 57 (47–67)% (P = 0.04). 
Thirteen patients (65%) and 82% of controls had total 
sperm counts above 39 million and progressive motile 
spermatozoa above 32% (P = 0.05), corresponding to 
the WHO 2010 reference levels for these variables 
(18). For the individual semen variables, there were no 
significant differences (patients vs controls) in semen 
volume 3.2 (1.4–5.6) vs 3.2 (2.3–4.3) mL (P = 0.47), sperm 
concentration 41 (11–71) vs 43 (22–73) mill/mL (P = 0.56) 
or total sperm counts 153 (15–288) vs 136 (65–235) mill 
(P = 0.66) (Fig. 4).
In univariate regression analyses, FSH was inversely 
associated with total sperm count, sperm concentration 
and inhibin b in the controls (all P < 0.001). By contrast, 
no significant association between FSH and total sperm 
counts (P = 0.77), sperm concentration (P = 0.58) or inhibin 
b (P = 0.87) were observed in the patients.
In patients (univariate regression analyses), levels 
of testosterone were positively associated with semen 
volume (P = 0.01) and total sperm counts (P = 0.03) 
(Fig. 5), but not with the sperm concentration (P = 0.14). 
In the controls, no significant associations were found 
between testosterone vs semen volume (P = 0.1), total 
sperm counts (P = 0.20) or sperm concentration (P = 0.06).
A diagnosis of acromegaly or a diagnosis of 
prolactinoma was not significantly associated with total 
sperm count or sperm concentration. IGF-I, prolactin, 
duration of abstinence from latest ejaculation, time 
since initial diagnose of pituitary disease or duration of 
documented androgen deficiency also did not predict 
semen quality.
Discussion
We report that a large proportion of patients with 
adult-onset pituitary disease presented with normal 
semen quality at the time when testosterone deficiency 
became apparent. The only significant difference we 
could document was a lower percentage of progressively 
motile spermatozoa in patients compared to controls. 
Thus, despite severe and highly significant reduction of 
Leydig cell function with low total and calculated free 
Figure 2
LH vs total testosterone (A) and LH vs calculated 
free testosterone (cfT) (B) in men with acquired 
hypogonadotropic hypogonadism plotted in a 
bivariate reference chart. The curves represent 
the 97.5 percentile for men from the general 
population (n = 706, age 20–50 years) (19). Points 
below the 97.5 percentile represent patients with 
an abnormal LH-testosterone (and LH-cfT) 
combination, and points above and to the left of 
both 97.5 percentiles represent individuals that 
have a normal combination.
Figure 3
FSH vs inhibin b in men with acquired hypogonadotropic hypogonadism 
plotted in a bivariate reference chart. The curves represent the 97.5 
percentile for proven fertile men (dotted line, n = 303, age 20–45 years) 
and the 97.5 percentile for men from the general population (full drawn 
line, n = 307, age 20–45 years) (20). Points above and to the left of both 
97.5 percentiles represent patients that have a normal FSH-inhibin b 
combination. Points placed between the two 97.5 percentiles represent 
individuals who are identified as having normal hormone levels in 
relation to men from the general population but outside the normal 
range in relation to proven fertile men.
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testosterone in all patients, the majority actually had 
normal semen quality. Therefore, the data suggest that the 
hypogonadotropic state influences the two components 
of the gonadal axis, steroidogenesis and spermatogenesis, 
differently. In support of this hypothesis serum FSH, in 
contrast to LH, was completely unchanged between 
patients and controls. Levels of inhibin b were reduced 
in the patients, but still the majority had serum inhibin 
b and FSH-inhibin b combination (bivariate plot) within 
normal range for proven fertile men.
It is well known, that development of pituitary 
insufficiency often follows a well-defined pattern with 
the growth hormone axis as the most frequently affected 
axis, followed by the gonadal axis, the thyroid axis and 
the adrenal axis (5, 23). As a novel observation, our data 
point to the possibility that in case of partial pituitary 
insufficiency spermatogenesis seems more robust than 
Leydig cell function. In patients with primary gonadal 
failure, the complete opposite scenario is often observed 
with severe suppression of spermatogenesis with preserved 
Leydig cell function (24).
To our knowledge, there are five studies investigating 
semen quality in patients with hyperprolactinemia naïve 
to treatment with testosterone or gonadotropins. Serum 
testosterone at baseline was in all studies comparable to 
the levels measured in our patients. Semen quality was 
reported to be reduced, but with very divergent results: 
In three studies, the sperm concentration at baseline 
was 6, 19 and 30 million/mL, respectively (8, 9, 10). 
The two remaining studies only reported total sperm 
counts (83 mill (11) and 44 mill, respectively (12). Two 
small studies (n = 6 and n = 7) found very poor semen 
quality with the majority having azoospermia in patients 
with acquired, and permanent secondary testosterone 
deficiency not caused by hyperprolactinemia (3, 25). A 
third study reported data from 10 infertile patients with 
adult-onset hypogonadotropic hypogonadism requiring 
gonadotropin treatment. Unfortunately, no specific data 
on baseline semen quality were provided in the paper, 
and it is unknown if the patients had been treated with 
testosterone prior to enrolment (4).
In agreement with the normal sperm counts our 
patients had testicular volume comparable with the 
healthy controls. By contrast, two previous studies found 
low sperm counts despite normal testicular size (3, 4). 
Thus, in patients with adult-onset hypogonadotropic 
hypogonadism, testicular size may not always be a 
predictor of semen quality. Compared to controls 
gynecomastia was more frequently observed in patients, 
despite reduced levels of estradiol. However, the estradiol/
Figure 4
Levels of FSH (A), sperm concentration (B) and total sperm counts (C) in controls and patients. All individual measurements are presented in the figure. 
Horizontal lines represent the median.
Figure 5
Relationship between testosterone vs semen 
volume (A) and total sperm counts (B) in patients 
with secondary hypogonadism.
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testosterone ratio was highly increased in the patients, 
supporting that it is the balance between androgens 
and estrogens that are important for development of 
gynecomastia in hypogonadal men and not the level of 
estradiol (26).
An important factor that should be considered is the 
duration of testosterone deficiency. During treatment 
with supraphysiological doses of testosterone and 
fully suppressed levels of FSH and LH, oligospermia 
and in many cases azoospermia, develops after around 
3–4 months (27). This is in agreement with the fact that 
formation of mature sperm takes approximately three 
months (28). In our study, testosterone deficiency was 
documented for a median of 3.5 months before evaluation 
of semen. Moreover, many of our patients already had low 
testosterone at the initial biochemical evaluation. Thus, 
the exact duration of low testosterone was unknown, but 
most likely significantly longer than the documented 
3.5 months.
The relative importance of intratesticular testosterone 
vs FSH stimulation on spermatogenesis in humans is 
debated. Intratesticular testosterone is believed to play a 
pivotal role for spermatogenesis and semen volume (1), 
although data obtained in the so-called fertile eunuch 
syndrome (congenital testosterone deficiency caused 
by isolated LH deficiency) show that spermatogenesis 
can be present despite low testosterone (29). The role 
of FSH in relation to spermatogenesis is less clear. In 
experimental models spermatogenesis can be induced 
by human chorionic gonadotropin (stimulation of LH 
receptors), in the absence of FSH, but FSH stimulation 
seems necessary to achieve complete restoration of 
spermatogenesis (1, 2). Thus, a synergic effect between 
FSH and intratesticular testosterone has been suggested 
(1). Despite low circulating testosterone in our study, the 
combined effect of intratesticular testosterone and FSH 
was sufficient to induce normal spermatogenesis in most 
patients. However, within the patients both semen volume 
and total sperm counts were positively associated with 
testosterone, supporting the importance of intratesticular 
testosterone.
Taken together, divergent results on semen quality in 
male patients with secondary testosterone deficiency have 
been published. We only identified serum testosterone 
as a predictor of semen quality and volume, whereas for 
example, underlying disease, levels of gonadotropins or 
levels of prolactin did not influence semen quality. Based 
on the available data from the present study duration of 
testosterone deficiency could also not be identified as a 
risk factor for poor semen quality. One of twenty patients 
had azoospermia, and therefore, we will still recommend 
early cryopreservation of semen in male patients with 
pituitary disease.
The diagnosis of hypogonadotropic testosterone 
deficiency was based on repeated measurements of low 
testosterone, reduced or normal serum concentration of 
LH and symptoms of testosterone deficiency. Moreover, 
there were structural changes in the pituitary on magnetic 
resonance imaging supporting a state of permanent 
pituitary insufficiency. Serum SHBG was reduced, 
which per se was unexpected in a testosterone deficient 
population (30). There could be several explanations 
including high levels of growth hormone/IGF-I in the 
acromegalic patients, insufficient replacement therapy 
with thyroxine and supraphysiological substitution 
therapy with hydrocortisone. Moreover, it cannot be 
excluded that higher BMI and higher age in patients 
compared to controls might have influenced SHBG. We 
did not have any valid information on tobacco smoking 
of the patients and can therefore not account for a 
possible effect on SHBG-levels. However, it should be 
emphasized that cfT was substantially reduced compared 
to both the control subjects, and to an age matched 
reference material.
FSH, LH and thyroid-stimulating hormone (TSH) 
belong to the glycoprotein hormone family. These 
hormones consist of a common alfa subunit and a unique 
beta subunit (31). The hormones are glycosylated, and it 
has been shown that alterations in glycosylation change 
the ratio between bioactivity and immunoreactivity 
(31). This phenomenon has been quite extensively 
investigated in respect to TSH in patients with central 
hypothyroidism, and it is now well established that TSH 
bioactivity is often reduced in patients with pituitary 
disease (32, 33). Analogous to these observations, our 
data showed reduced testosterone/LH ratio, reduced 
cfT/LH ratio, and using bivariate plots, we observed an 
abnormal relationship between total-testosterone and 
cfT vs the corresponding LH in the majority of patients. 
Thus, we speculate that the bioactivity of LH might be 
reduced in male patients with central hypogonadism. 
This is to our knowledge a new observation. Alternatively, 
the findings should reflect that patients with pituitary 
disease in general also had a primary testicular failure, 
which we consider unlikely. Concerning FSH bioactivity 
our results are less clear. Reduced inhibin b/FSH ratio in 
patients point to the possibility of reduced bioactivity. 
On the other hand, the majority had serum inhibin b 
and FSH-inhibin b combination (bivariate plot) within 
normal range for proven fertile men, and they had 
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normal sperm counts supporting sufficient bioactivity. 
One previous study has investigated FSH bioactivity in 
male patients with non-functioning pituitary adenomas 
and found unchanged in vitro FSH bioactivity. By 
contrast clinically relevant changes in the bioactivity of 
gonadotropins have been documented in other clinical 
conditions such as anorexia nervosa (34), polycystic 
ovarian disease (35) and primary male hypogonadism 
(36). Thus, as for TSH, immunoreactive FSH and LH 
may not reflect FSH and LH bioactivity in patients with 
pituitary disease, and even a stimulation test probably 
does not add to the correct diagnosis, since secretion 
of the dysglycosylated molecules can be stimulated by 
hypothalamic hormones (32, 37). We acknowledge that 
the hypothesis of reduced bioactivity of gonadotropins 
is based on speculations and this topic merits further 
investigations.
There are several limitations to the presented 
study. The control subjects were not matched for age, 
but we do not believe that it is a major confounder, 
since there only seems to be minor changes in semen 
quality (38) and circulating testosterone levels (39) in 
individuals aged 20 vs 30  years. We studied a highly 
selected inhomogeneous group of patients comprising 
a small non-representative fraction of the entire 
group of patients diagnosed with hypogonadotropic 
hypogonadism at our department (n = 409). The 
participants in the study were significantly younger 
and comprised a large fraction of patients with growth 
hormone excess, which might per se have a negative 
influence on semen quality (40). Finally, we did not have 
data on sperm morphology. There are data suggesting 
that morphology is affected in patients with secondary 
hypogonadism due to thalassemia (41).
In conclusion, despite severe testosterone deficiency, 
13 of 20 patients had normal semen quality based on the 
2010 WHO criteria for total sperm counts and motility. 
We will recommend, that all patients with secondary 
testosterone deficiency are offered cryopreservation 
of semen, before initiation of testosterone therapy. 
In many cases, cryopreserved semen seems to be 
of sufficient quality for fertility treatment. With 
this approach the patient and his partner have the 
opportunity to decide, if they prefer fertility treatment 
with cryopreserved semen or testosterone treatment 
withdrawal, and medical induction of spermatogenesis 
with gonadotropins, which would be the alternative 
treatment. Finally, our data point to the possibility that 
bioactivity of gonadotropins may be reduced in patients 
with pituitary insufficiency.
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